<article title='Creutzfeldt%E2%80%93Jakob_disease'><paragraph><template><target>bots</target><arg name="deny">Monkbot7</arg></template><space/><template><target>Infobox disease</target><arg name="Name"><space/>Creutzfeldt&ndash;Jakob disease
</arg><arg name="Image"><space/>VCJD Tonsil.jpg
</arg><arg name="Caption"><space/>Tonsil biopsy in variant CJD. Prion protein immunostaining.
</arg><arg name="field"><space/>[[Neurology]]
</arg><arg name="DiseasesDB"><space/>3166
</arg><arg name="ICD10"><space/>{{ICD10|A|81|0|a|80}}, {{ICD10|F|02|1|f|00}}
</arg><arg name="ICD9"><space/>{{ICD9|046.1}}
</arg><arg name="ICDO">
</arg><arg name="OMIM"><space/>123400
</arg><arg name="MedlinePlus"><space/>000788
</arg><arg name="eMedicineSubj"><space/>neuro
</arg><arg name="eMedicineTopic"><space/>725
</arg><arg name="MeshID"><space/>D007562
</arg></template></paragraph><paragraph><bold>Creutzfeldt&amp;ndash;Jakob disease</bold><space/>(<template><target>IPAc-en</target><arg>ˈ</arg><arg>k</arg><arg>r</arg><arg>ɔɪ</arg><arg>t</arg><arg>s</arg><arg>f</arg><arg>ɛ</arg><arg>l</arg><arg>t</arg><arg>_</arg><arg>ˈ</arg><arg>j</arg><arg>ɑː</arg><arg>k</arg><arg>oʊ</arg><arg>b</arg></template><space/><template><target>respell</target><arg>KROITS</arg><arg>felt</arg></template><space/><template><target>respell</target><arg>YAH</arg><arg>kohb</arg></template>)<extension extension_name='ref'>Merriam-Webster's Collegiate Dictionary</extension><space/>or<space/><bold>CJD</bold><space/>is a<space/><link><target>Neurodegenerative disease</target><part>degenerative neurological disease</part></link><space/>that is incurable and invariably fatal.<extension extension_name='ref' name="CDC1"><template><target>cite web</target><arg name="title"><space/>CJD (Creutzfeldt–Jakob Disease, Classic)
<space/></arg><arg name="url"><space/>http://www.cdc.gov/ncidod/dvrd/cjd/index.htm
<space/></arg><arg name="publisher"><space/>Centers for Disease Control and Prevention
<space/></arg><arg name="date"><space/>2008-02-26
<space/></arg><arg name="accessdate"><space/>2009-06-20
</arg></template></extension><space/>CJD is at times called a human form of mad cow disease (<link><target>bovine spongiform encephalopathy</target></link><space/>or BSE).<extension extension_name='ref' name="PubMed Health"><template><target>cite news</target><arg name="title">Creutzfeldt–Jakob disease: Transmissible spongiform encephalopathy; vCJD; CJD; Jacob-Creutzfeldt disease<space/></arg><arg name="author">VeriMed Healthcare Network, reviewed by: David C. Dugdale, Luc Jasmin,David Zieve<space/></arg><arg name="url">http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001792/</arg><arg name="publisher"><space/>U.S. National Library of Medicine<space/></arg><arg name="date"><space/>2011-09-26</arg><arg name="accessdate"><space/>2012-04-25</arg></template></extension><space/>However, given that BSE is believed to be the cause of variant CreutzfeldtJakob (vCJD) disease in humans, the two are often confused.<extension extension_name='ref' name="British Medical Journal"><template><target>cite news</target><arg name="title"><space/>Bovine spongiform encephalopathy and variant Creutzfeldt–Jakob disease<space/></arg><arg name="author">Paul Brown<space/></arg><arg name="url"><space/>http://www.bmj.com/content/322/7290/841.full<space/></arg><arg name="publisher"><space/>[[BMJ]]<space/></arg><arg name="date"><space/>2001-07-04<space/></arg><arg name="accessdate"><space/>2011-02-23</arg></template></extension></paragraph><paragraph>CJD is caused by an agent called a<space/><link><target>prion</target></link>. Prions are misfolded proteins that replicate by converting their properly folded counterparts, in their host, to the same misfolded structure they possess. CJD causes the brain tissue to degenerate rapidly, and as the disease destroys the brain, the brain develops holes and the texture changes to resemble that of a kitchen sponge.</paragraph><heading level='2'>Classification</heading><paragraph>Types of CJD include:</paragraph><list type='bullet'><listitem>variant (vCJD):<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Ironside</arg><arg name="first">JW</arg><arg name="author2">Sutherland, K<space/></arg><arg name="author3">Bell, JE<space/></arg><arg name="author4">McCardle, L<space/></arg><arg name="author5">Barrie, C<space/></arg><arg name="author6">Estebeiro, K<space/></arg><arg name="author7">Zeidler, M<space/></arg><arg name="author8">Will, RG<space/></arg><arg name="title">A new variant of Creutzfeldt–Jakob disease: neuropathological and clinical features.</arg><arg name="journal">Cold Spring Harbor symposia on quantitative biology</arg><arg name="year">1996</arg><arg name="volume">61</arg><arg name="pages">523–30</arg><arg name="pmid">9246478</arg><arg name="doi">10.1101/SQB.1996.061.01.052</arg></template></extension></listitem></list><list type='ident'><listitem>This is thought to be caused by the consumption of food contaminated with<space/><link><target>prions</target></link>, which also cause<space/><link><target>Bovine spongiform encephalopathy</target><part>BSE</part></link>.</listitem></list><list type='bullet'><listitem>sporadic (sCJD):<extension extension_name='ref' name="pmid18410280"><template><target>cite journal</target><arg name="author">Niimi Y, Iwasaki Y, Umemura T<space/></arg><arg name="title">MM2-cortical-type sporadic Creutzfeldt–Jakob disease with early stage cerebral cortical pathology presenting with a rapidly progressive clinical course<space/></arg><arg name="journal">Neuropathology<space/></arg><arg name="volume">28<space/></arg><arg name="issue">6<space/></arg><arg name="pages">645–51<space/></arg><arg name="date">December 2008<space/></arg><arg name="pmid">18410280<space/></arg><arg name="doi">10.1111/j.1440-1789.2008.00904.x<space/></arg><arg name="url">http://www3.interscience.wiley.com/resolve/openurl?genre</arg></template></extension><space/></listitem></list><list type='ident'><listitem>This accounts for 85% of cases of CJD.<extension extension_name='ref' name="whoint"></extension></listitem></list><list type='bullet'><listitem>familial (fCJD):<extension extension_name='ref' name="luga"><template><target>cite journal</target><arg name="last">Lugaresi</arg><arg name="first">E</arg><arg name="author2">Medori, R<space/></arg><arg name="author3">Montagna, P<space/></arg><arg name="author4">Baruzzi, A<space/></arg><arg name="author5">Cortelli, P<space/></arg><arg name="author6">Lugaresi, A<space/></arg><arg name="author7">Tinuper, P<space/></arg><arg name="author8">Zucconi, M<space/></arg><arg name="author9"><space/>Gambetti, P<space/></arg><arg name="title">Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei</arg><arg name="journal">The New England Journal of Medicine</arg><arg name="date">Oct 16, 1986</arg><arg name="volume">315</arg><arg name="issue">16</arg><arg name="pages">997–1003</arg><arg name="pmid">3762620</arg><arg name="doi">10.1056/NEJM198610163151605</arg></template></extension><space/></listitem></list><list type='ident'><listitem>This accounts for the majority of the other 15% cases of CJD.<extension extension_name='ref' name="whoint"></extension></listitem></list><list type='bullet'><listitem>iatrogenic:<space/></listitem></list><list type='ident'><listitem>This form of CJD arises from contamination with tissue from an infected person, usually as the result of a medical procedure. Medical procedures that are associated with the spread of this form of CJD include blood transfusion from the infected person, use of human-derived pituitary growth hormones,<extension extension_name='ref' name="ricketts"></extension><space/>gonadotropin hormone therapy,<extension extension_name='ref' name="ricketts"></extension><space/>corneal and/or meningeal transplants.<extension extension_name='ref' name="whoint"><link type='external' href='http://www.who.int/mediacentre/factsheets/fs180/en/'>who.int: &quot;Fact sheets no 180: Variant Creutzfeldt-Jakob disease&quot; Feb 2012 ed.</link></extension></listitem></list><heading level='2'>Signs and symptoms</heading><preblock><preline>The first symptom of CJD is rapidly progressive<space/><link><target>dementia</target></link>, leading to<space/><link><target>memory</target></link><space/>loss,<space/><link><target>Personality psychology</target><part>personality</part></link><space/>changes, and<space/><link><target>hallucinations</target></link>. Other frequently occurring features include<space/><link><target>anxiety</target></link>,<space/><link><target>depression (mood)</target><part>depression</part></link>,<space/><link><target>paranoia</target></link>,<space/><link><target>obsessive-compulsive</target></link><space/>symptoms, and<space/><link><target>psychosis</target></link>.<extension extension_name='ref'>Murray ED, Buttner N, Price BH. (2012) Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6th Edition. Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.) Butterworth Heinemann. April 12, 2012. ISBN 1437704344 | ISBN 978-1437704341</extension><space/>This is accompanied by physical problems such as<space/><link><target>Speech communication</target><part>speech</part></link><space/>impairment, jerky movements (<link><target>myoclonus</target></link>), balance and coordination dysfunction (<link><target>ataxia</target></link>), changes in<space/><link><target>gait (human)</target><part>gait</part></link>, rigid<space/><link><target>Human position</target><part>posture</part></link>, and<space/><link><target>seizures</target></link>. The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks.<template><target>citation needed</target><arg name="date">October 2013</arg></template><space/>In some people, the symptoms can continue for years. In most patients, these symptoms are followed by<space/><link><target>Dyskinesia</target><part>involuntary movements</part></link><space/>and the appearance of an atypical diagnostic<space/><link><target>electroencephalogram</target></link><space/>tracing. Most victims die six months after initial symptoms appear, often of<space/><link><target>pneumonia</target></link><space/>due to impaired coughing reflexes. About 15% of patients survive for two or more years.<extension extension_name='ref' name="Gambetti"><template><target>cite web</target><arg name="last">Gambetti</arg><arg name="first">Pierluigi</arg><arg name="title">Creutzfeldt–Jakob Disease (CJD)</arg><arg name="url">http://www.merckmanuals.com/home/sec06/ch090/ch090b.html</arg><arg name="publisher">The Merck Manuals: Online Medical Library</arg><arg name="accessdate">4/6/11</arg></template></extension><space/>Some patients have been known to live 45 years with mostly psychological symptoms until the disease progresses causing more physical symptoms leading to a diagnosis and inevitable death usually within the first year of diagnosis.</preline></preblock><paragraph>The symptoms of CJD are caused by the progressive<space/><link><target>cell death</target><part>death</part></link><space/>of the brain's<space/><link><target>neuron</target><part>nerve cells</part></link>, which is associated with the build-up of abnormal prion proteins forming<space/><link><target>amyloids</target></link>. When brain tissue from a CJD patient is examined under a<space/><link><target>microscope</target></link>, many tiny holes can be seen where whole areas of nerve cells have died. The word &quot;spongiform&quot; in &quot;<link><target>transmissible spongiform encephalopathies</target></link>&quot; refers to the sponge-like appearance of the brain tissue.</paragraph><heading level='2'>Cause</heading><paragraph>Transmissible spongiform encephalopathy diseases are caused by<space/><link><target>prion</target><trail>s</trail></link>. Prions are proteins that occur normally in neurons of the central nervous system (CNS).<space/><template><target>As of</target><arg>2007</arg></template>, these proteins are thought to affect signaling processes, damaging neurons and resulting in degeneration that causes the spongiform appearance in the affected brain.<extension extension_name='ref'><template><target>cite book</target><arg name="title"><space/>Fundamentals of Pathology
author<space/></arg></template></extension></paragraph><paragraph>The CJD prion is dangerous because it promotes<space/><link><target>Protein folding</target><part>refolding</part></link><space/>of native proteins into the diseased state.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Clarke</arg><arg name="first">AR</arg><arg name="author2">Jackson, GS<space/></arg><arg name="author3">Collinge, J<space/></arg><arg name="title">The molecular biology of prion propagation</arg><arg name="journal">Philosophical transactions of the Royal Society of London. Series B, Biological sciences</arg><arg name="date">Feb 28, 2001</arg><arg name="volume">356</arg><arg name="issue">1406</arg><arg name="pages">185–95</arg><arg name="pmid">11260799</arg><arg name="doi">10.1098/rstb.2000.0764</arg><arg name="pmc">1088424</arg></template></extension><space/>The number of misfolded protein molecules will increase<space/><link><target>exponential growth</target><part>exponentially</part></link><space/>and the process leads to a large quantity of insoluble protein in affected<space/><link><target>cell (biology)</target><part>cells</part></link>. This mass of misfolded proteins disrupts neuronal cell function and causes cell death. Mutations in the gene for the prion protein can cause a misfolding of the dominantly alpha helical regions into beta pleated sheets. This change in conformation disables the ability of the protein to undergo digestion. Once the prion is transmitted, the defective proteins invade the brain and are produced in a self-sustaining<space/><link><target>feedback loop</target></link>.<template><target>mcn</target><arg name="date">May 2015</arg></template></paragraph><paragraph>These neurodegenerative diseases are commonly called<space/><italics><link><target>prion disease</target><trail>s</trail></link></italics>.</paragraph><paragraph>People can also acquire CJD genetically through a mutation of the gene that codes for the prion protein (PRNP). This occurs in only 5-10% of all CJD cases. An EU study determined that &quot;87% of cases were sporadic, 8% genetic, and 5% iatrogenic.&quot;<space/><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Will, R. G.
</arg><arg name="author2">Alperovitch, A.
</arg><arg name="author3">Poser, S.
</arg><arg name="author4">Pocchiari, M.
</arg><arg name="author5">Hofman, A.
</arg><arg name="author6">Mitrova, E.
</arg><arg name="author7">de Silva, R.
</arg><arg name="author8">D'Alessandro, M.
</arg><arg name="author9">Delasnerie-Laupretre, N.
</arg><arg name="author10">Zerr, I.
</arg><arg name="author11">van Duijn, C.
</arg><arg name="title">EU collaborative Study Group for CJD (1998), Descriptive epidemiology of Creutzfeldt-Jakob disease in six european countries, 1993–1995
</arg><arg name="date">1998
</arg><arg name="volume">43
</arg><arg name="pages">763–767
</arg><arg name="doi">10.1002/ana.410430611
</arg></template></extension></paragraph><heading level='3'>Transmission</heading><paragraph>The defective protein can be transmitted by contaminated harvested human brain products,<extension extension_name='ref'>In July 2012, Greenville Memorial Hospital in South Carolina released a public warning after warning eleven other patients that a brain surgery patient was later diagnosed with CJD, and though workers sterilized instruments, the hospital stated the CJD patient's diagnosis wasn't known at the time of the surgery and it wanted to warn other patients out of an abundance of caution, noting the CDC recommendation for additional instrument cleaning when CJD is suspected. See Collins, Jeffrey,<space/><link type='external' href='http://www.thestate.com/2012/08/01/2377658/hospital.html'>Greenville hospital warns of rare brain disease</link>,<space/><italics>The State</italics>, thestate.com, 2012-8-1; and Osby, Liv,<space/><link type='external' href='http://www.greenvilleonline.com/apps/pbcs.dll/article?AID=2012307310017&amp;amp;nclick_check=0'>11 patients may have been exposed to fatal disease</link>,<space/><italics>The Greenville News</italics>, greenvilleonline.com, 2012-7-31.</extension><space/><link><target>cornea</target><trail>l</trail></link><space/>grafts (in at least one reported case),<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Armitage</arg><arg name="first1">W J</arg><arg name="last2">Tullo</arg><arg name="first2">A B</arg><arg name="last3">Ironside</arg><arg name="first3">J W</arg><arg name="title">Risk of Creutzfeldt–Jakob disease transmission by ocular surgery and tissue transplantation</arg><arg name="journal">Eye</arg><arg name="date">9 January 2009</arg><arg name="volume">23</arg><arg name="issue">381</arg><arg name="page">1928</arg><arg name="url">http://www.nature.com/eye/journal/v23/n10/full/eye2008381a.html#aff1</arg><arg name="accessdate">16 January 2015</arg><arg name="doi">10.1038/eye.2008.381</arg></template></extension><space/><link><target>Dura mater</target><part>dural</part></link><space/>grafts or<space/><link><target>electrode</target></link><space/>implants (acquired or<space/><link><target>Iatrogenesis</target><part>iatrogenic</part></link><space/>form (iCJD)); it can be familial (fCJD); or it may appear for the first time in the patient (sporadic form: sCJD). In the familial form, a<space/><link><target>mutation</target></link><space/>occurs in the<space/><link><target>gene</target></link><space/>for PrP,<space/><link><target>PRNP</target></link>. Ten to fifteen percent of CJD cases are familial. (CDC)</paragraph><paragraph>The disease has also been shown to result from use of<space/><link><target>human growth hormone</target></link><space/>obtained from the<space/><link><target>pituitary gland</target><trail>s</trail></link><space/>of persons who died from Creutzfeldt&amp;ndash;Jakob Disease,<extension extension_name='ref' name="titleHGH Linked to Brain Eater"><template><target>cite journal</target><arg name="author"><space/>Mills JL, Schonberger LB, Wysowski DK
</arg><arg name="title"><space/>Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients
</arg><arg name="journal"><space/>The Journal of Pediatrics
</arg><arg name="volume"><space/>144
</arg><arg name="issue"><space/>4
</arg><arg name="pages"><space/>430–6
</arg><arg name="date">April 2004
</arg><arg name="pmid"><space/>15069388
</arg><arg name="doi"><space/>10.1016/j.jpeds.2003.12.036
</arg><arg name="laysummary"><space/>http://www.wired.com/medtech/health/news/2004/04/62998
</arg><arg name="laysource"><space/>Wired
</arg><arg name="laydate"><space/>2004-04-09
</arg></template></extension><space/>though the known incidence of this cause is (<template><target>asof</target><arg>2004</arg><arg>04</arg><arg name="lc">yes</arg></template>) quite small. The risk of infection via cadaveric HGH in the US ceased when the medication was withdrawn in 1985.<template><target>citation needed</target><arg name="date">March 2014</arg></template></paragraph><paragraph>It is thought that humans can contract the disease by consuming material from animals infected with the bovine form of the disease.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Collinge</arg><arg name="first">J</arg><arg name="author2">Sidle, KC<space/></arg><arg name="author3">Meads, J<space/></arg><arg name="author4">Ironside, J<space/></arg><arg name="author5"><space/>Hill, AF<space/></arg><arg name="title">Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD</arg><arg name="journal">Nature</arg><arg name="date">Oct 24, 1996</arg><arg name="volume">383</arg><arg name="issue">6602</arg><arg name="pages">685–90</arg><arg name="pmid">8878476</arg><arg name="doi">10.1038/383685a0</arg></template></extension><space/>The only suspected cases to arise thus far have been vCJD with cases in the UK and Canada. But there are also fearsbased on animal studies<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Bruce<space/></arg><arg name="first1"><space/>M.E.
<space/></arg><arg name="author1-link"><space/>
<space/></arg><arg name="last2"><space/>Will<space/></arg><arg name="first2"><space/>R.G.
<space/></arg><arg name="author2-link"><space/>
<space/></arg><arg name="last3"><space/>Ironside<space/></arg><arg name="first3"><space/>J.W.
<space/></arg><arg name="author3-link"><space/>
<space/></arg><arg name="last4"><space/>McConnell<space/></arg><arg name="first4"><space/>I.
<space/></arg><arg name="author4-link"><space/>
<space/></arg><arg name="last5"><space/>Drummond<space/></arg><arg name="first5"><space/>D
<space/></arg><arg name="author5-link"><space/>
<space/></arg><arg name="last6"><space/>Suttie<space/></arg><arg name="first6"><space/>A.
<space/></arg><arg name="author6-link"><space/>
<space/></arg><arg name="last7"><space/>McCardle<space/></arg><arg name="first7"><space/>L.
<space/></arg><arg name="author7-link"><space/>
<space/></arg><arg name="last8"><space/>Chree<space/></arg><arg name="first8"><space/>A.
<space/></arg><arg name="author8-link"><space/>
<space/></arg><arg name="last9"><space/>Hope<space/></arg><arg name="first9"><space/>J.
<space/></arg><arg name="author9-link"><space/>
<space/></arg><arg name="last10"><space/>Birkett<space/></arg><arg name="first10"><space/>C.
<space/></arg><arg name="author10-link"><space/>
<space/></arg><arg name="last11"><space/>Cousens<space/></arg><arg name="first11"><space/>S.
<space/></arg><arg name="author11-link"><space/>
<space/></arg><arg name="last12"><space/>Fraser<space/></arg><arg name="first12"><space/>H.
<space/></arg><arg name="author12-link"><space/>
<space/></arg><arg name="last13"><space/>Bostock<space/></arg><arg name="first13"><space/>C.J.
<space/></arg><arg name="author13-link"><space/>
<space/></arg><arg name="title"><space/>Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent
<space/></arg><arg name="journal"><space/>Nature
<space/></arg><arg name="volume"><space/>389
<space/></arg><arg name="issue"><space/>6650
<space/></arg><arg name="pages"><space/>498–501
<space/></arg><arg name="publisher"><space/>Nature Publishing Group
<space/></arg><arg name="location"><space/>NY, NY
<space/></arg><arg name="date"><space/>October 2, 1997
<space/></arg><arg name="url"><space/>http://www.nature.com/nature/journal/v389/n6650/full/389498a0.html?free</arg><arg name="jstor">
<space/></arg><arg name="issn"><space/>0028-0836
<space/></arg><arg name="doi"><space/>10.1038/39057
<space/></arg><arg name="id">
<space/></arg><arg name="mr">
<space/></arg><arg name="zbl">
<space/></arg><arg name="jfm">
<space/></arg><arg name="accessdate"><space/>April 25, 2012
<space/></arg><arg name="pmid"><space/>9333239</arg></template></extension>that consuming beef or beef products containing prion particles can also cause the development of classic CJD. When BSE material infects humans, the resulting disease is known as (new) variant CJD (nvCJD).<extension extension_name='ref' name="nwanebuafrican1"><template><target>cite journal</target><arg name="author"><space/>Obi RK, Nwanebu FC
</arg><arg name="year"><space/>2008
</arg><arg name="title"><space/>Prions And Prion Diseases
</arg><arg name="journal"><space/>African Journal of Clinical and Experimental Microbiology
</arg><arg name="volume"><space/>9
</arg><arg name="issue"><space/>1
</arg><arg name="pages"><space/>38–52
</arg><arg name="issn"><space/>1595-689X
</arg><arg name="url"><space/>http://ajol.info/index.php/ajcem/article/view/7481
</arg><arg name="accessdate"><space/>2009-06-20
</arg><arg name="doi"><space/>10.4314/ajcem.v9i1.7481
</arg></template></extension></paragraph><paragraph><link><target>Cannibalism</target></link><space/>has also been implicated as a transmission mechanism for abnormal prions, causing the disease known as<space/><link><target>Kuru (disease)</target><part>kuru</part></link>, once found primarily among women and children of the<space/><link><target>Fore people</target></link><space/>in<space/><link><target>Papua New Guinea</target></link>. While the men of the tribe ate the body of the deceased and rarely contracted the disease, the women and children, who ate the less desirable body parts, including the brain, were eight times more likely than men to contract kuru from infected tissue.</paragraph><paragraph>Prions, the<space/><link><target>infectious agent</target></link><space/>of CJD, may not be inactivated by means of routine<space/><link><target>surgical instrument</target></link><space/><link><target>Autoclave</target><part>sterilization</part></link><space/>procedures. The<space/><link><target>World Health Organization</target></link><space/>and the US<space/><link><target>Centers for Disease Control and Prevention</target></link><space/>recommend that instrumentation used in such cases be immediately destroyed after use; short of destruction, it is recommended that heat and chemical decontamination be used in combination to process instruments that come in contact with high-infectivity tissues. No cases of iatrogenic transmission of CJD have been reported subsequent to the adoption of current sterilization procedures, or since 1976.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Questions and Answers: Creutzfeldt-Jakob Disease Infection-Control Practices</arg><arg name="work">Infection Control Practices/CJD (Creutzfeldt-Jakob Disease, Classic)</arg><arg name="publisher">Centers for Disease Control and Prevention</arg><arg name="date">January 4, 2007</arg><arg name="url"><space/>http://www.cdc.gov/ncidod/dvrd/cjd/qa_cjd_infection_control.htm#sterilization</arg><arg name="accessdate"><space/>2007-06-09</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies</arg><arg name="publisher">World Health Organization: Communicable Disease Surveillance and Control</arg><arg name="date">26 March 1999</arg><arg name="url">http://www.who.int/csr/resources/publications/bse/WHO_CDS_CSR_APH_2000_3/en/</arg><arg name="accessdate"><space/>2007-06-09</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McDonnell G, Burke P
</arg><arg name="title"><space/>The challenge of prion decontamination
</arg><arg name="journal"><space/>Clinical Infectious Diseases
</arg><arg name="volume"><space/>36
</arg><arg name="issue"><space/>9
</arg><arg name="pages"><space/>1152–4
</arg><arg name="date">May 2003
</arg><arg name="pmid"><space/>12715310
</arg><arg name="doi"><space/>10.1086/374668
</arg></template></extension><space/><link><target>Copper</target></link>-<link><target>hydrogen peroxide</target></link><space/>has been suggested as an alternative to the current recommendation of<space/><link><target>sodium hydroxide</target></link><space/>or<space/><link><target>sodium hypochlorite</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Solassol J, Pastore M, Crozet C<space/></arg><arg name="title">A novel copper-hydrogen peroxide formulation for prion decontamination<space/></arg><arg name="journal">J Infect Dis<space/></arg><arg name="year">2006<space/></arg><arg name="volume">194<space/></arg><arg name="pages">865–869<space/></arg><arg name="doi">10.1086/506947<space/></arg><arg name="pmid">16941355<space/></arg><arg name="issue">6<space/></arg></template></extension><space/><link><target>Thermal depolymerization</target></link><space/>also destroys prions in infected organic and inorganic matter, since the process chemically attacks protein at the molecular level, although more effective and practical methods involve destruction by combinations of detergents and enzymes similar to biological washing powders.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Jackson</arg><arg name="first">GS</arg><arg name="author2">McKintosh, E<space/></arg><arg name="author3">Flechsig, E<space/></arg><arg name="author4">Prodromidou, K<space/></arg><arg name="author5">Hirsch, P<space/></arg><arg name="author6">Linehan, J<space/></arg><arg name="author7">Brandner, S<space/></arg><arg name="author8">Clarke, AR<space/></arg><arg name="author9">Weissmann, C<space/></arg><arg name="author10"><space/>Collinge, J<space/></arg><arg name="title">An enzyme-detergent method for effective prion decontamination of surgical steel</arg><arg name="journal">The Journal of general virology</arg><arg name="date">March 2005</arg><arg name="volume">86</arg><arg name="issue">Pt 3</arg><arg name="pages">869–78</arg><arg name="pmid">15722550</arg><arg name="doi">10.1099/vir.0.80484-0</arg></template></extension></paragraph><heading level='3'>Blood donor restrictions</heading><paragraph>In 2004, a report published in the<space/><italics><link><target>The Lancet</target><part>Lancet</part></link></italics><space/>medical journal showed that vCJD can be transmitted by<space/><link><target>blood transfusion</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid15302196"><template><target>cite journal</target><arg name="author">Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW<space/></arg><arg name="title">Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient<space/></arg><arg name="journal">Lancet<space/></arg><arg name="volume">364<space/></arg><arg name="issue">9433<space/></arg><arg name="pages">527–9<space/></arg><arg name="year">2004<space/></arg><arg name="pmid">15302196<space/></arg><arg name="doi">10.1016/S0140-6736(04)16811-6</arg></template></extension><space/>The finding alarmed healthcare officials because a large<space/><link><target>epidemic</target></link><space/>of the disease could result in the near-future. A blood test for vCJD infection is possible<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Edgeworth</arg><arg name="first">JA<space/></arg><arg name="author2">Farmer, M<space/></arg><arg name="author3">Sicilia, A<space/></arg><arg name="author4">Tavares, P<space/></arg><arg name="author5">Beck, J<space/></arg><arg name="author6">Campbell, T<space/></arg><arg name="author7">Lowe, J<space/></arg><arg name="author8">Mead, S<space/></arg><arg name="author9">Rudge, P<space/></arg><arg name="author10">Collinge, J<space/></arg><arg name="author11">Jackson, GS</arg><arg name="title">Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay</arg><arg name="journal">Lancet</arg><arg name="date">Feb 5, 2011</arg><arg name="volume">377</arg><arg name="issue">9764</arg><arg name="pages">487–93</arg><arg name="pmid">21295339</arg><arg name="doi">10.1016/S0140-6736(10)62308-2</arg></template></extension><space/>but is not yet available for screening blood donations. Significant restrictions exist to protect the blood supply. The<space/><link><target>UK government</target></link><space/>banned anyone who had received a blood transfusion since January 1980 from donating blood.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Variant CJD and blood donation
<space/></arg><arg name="url"><space/>http://www.blood.co.uk/pdfdocs/vcjd.pdf
<space/></arg><arg name="publisher"><space/>National Blood Service
<space/></arg><arg name="format"><space/>PDF
<space/></arg><arg name="date">August 2004
<space/></arg><arg name="accessdate"><space/>2009-06-20
</arg></template><space/><template><target>Dead link</target><arg name="date">October 2010</arg><arg name="bot">H3llBot</arg></template></extension><space/>From 1999 there has been a ban in the UK for using UK blood to manufacture fractional products such as<space/><link><target>albumin</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Regan F, Taylor C
</arg><arg name="title"><space/>Blood transfusion medicine
</arg><arg name="journal"><space/>BMJ (Clinical Research Ed.)
</arg><arg name="volume"><space/>325
</arg><arg name="issue"><space/>7356
</arg><arg name="pages"><space/>143–7
</arg><arg name="date">July 2002
</arg><arg name="pmid"><space/>12130612
</arg><arg name="pmc"><space/>1123672
</arg><arg name="doi"><space/>10.1136/bmj.325.7356.143
</arg></template></extension><space/>Whilst these restrictions may go some way to preventing a self-sustaining epidemic of secondary infections the number of infected blood donations is unknown and could be considerable as a study by the Health Protection Agency show around 1 in 2000 people in the UK shows signs of vCJD infection.<extension extension_name='ref' name="Health Protect Report"><template><target>cite web</target><arg name="last">HPA Press Office</arg><arg name="title">Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens</arg><arg name="url">http://www.hpa.org.uk/hpr/archives/2012/news3212.htm#bnrmlprn</arg><arg name="date">August 10, 2012</arg></template></extension><space/>In June 2013 the government was warned that deathsthen at 176could rise five-fold through blood transfusions.<extension extension_name='ref' name="rowena"><template><target>cite news</target><arg name="url">http://www.telegraph.co.uk/health/healthnews/10024078/Mad-cow-infected-blood-to-kill-1000.html</arg><arg name="title">Mad cow infected blood 'to kill 1,000'</arg><arg name="author">Rowena Mason</arg><arg name="work">Daily Telegraph</arg><arg name="date">April 28, 2013</arg><arg name="accessdate">July 2, 2013</arg><arg name="location">London</arg></template></extension></paragraph><paragraph>On May 28, 2002, the<space/><link><target>United States</target></link><space/><link><target>Food and Drug Administration</target></link><space/>instituted a policy that excludes from donation anyone having spent at least six months in certain European countries (or three months in the United Kingdom) from 1980 to 1996. Given the large number of U.S. military personnel and their dependents residing in Europe, it was expected that over 7% of donors would be deferred due to the policy. Later changes to this policy have relaxed the restriction to a cumulative total of five years or more of civilian travel in European countries (six months or more if military). The three-month restriction on travel to the UK, however, has not been changed.<extension extension_name='ref' name="titleIn-Depth Discussion of Variant Creutzfeld-Jacob Disease and Blood Donation"><template><target>cite web</target><arg name="title"><space/>In-Depth Discussion of Variant Creutzfeld-Jacob Disease and Blood Donation
<space/></arg><arg name="url"><space/>http://www.redcross.org/services/biomed/blood/supply/cjdv.html
<space/></arg><arg name="archiveurl"><space/>http://web.archive.org/web/20071230205118/http://www.redcross.org/services/biomed/blood/supply/cjdv.html
<space/></arg><arg name="publisher"><space/>American Red Cross
<space/></arg><arg name="archivedate"><space/>2007-12-30
<space/></arg><arg name="accessdate"><space/>2009-06-20
</arg></template></extension></paragraph><paragraph>The<space/><link><target>American Red Cross</target></link>' policy is as follows: During the period January 1, 1980, to December 31, 1996, spending a total time of three months or more in the<space/><link><target>Channel Islands</target></link>,<space/><link><target>England</target></link>, the<space/><link><target>Falkland Islands</target></link>, the<space/><link><target>Isle of Man</target></link>,<space/><link><target>Gibraltar</target></link>,<space/><link><target>Northern Ireland</target></link>,<space/><link><target>Scotland</target></link>, and<space/><link><target>Wales</target></link><space/>precludes individuals from donating. Moreover, spending a total time of five years or more after January 1, 1980 (to present), in the above-mentioned countries and/or any country in Europe (except the former USSR), also precludes donation. People with a biologic relative having been diagnosed with CJD or vCJD are unable to donate. Biologic relative in this setting means mother, father, sibling, grandparent, aunt, uncle, or child.</paragraph><paragraph>A similar policy applies to potential donors to the<space/><link><target>Australian Red Cross</target></link>'<space/><link><target>Australian Red Cross Blood Service</target><part>Blood Service</part></link>, precluding people who have spent a cumulative time of six months or more in the United Kingdom between 1980 and 1996.</paragraph><paragraph>The<space/><link><target>Singapore Red Cross</target></link><space/>precludes potential donors having spent a cumulative time of three months or more in the United Kingdom between 1980 and 1996.</paragraph><paragraph>In New Zealand, the<space/><link><target>New Zealand Blood Service</target></link><space/>(NZBS) in 2000 introduced measures to preclude permanently donors having resided in the United Kingdom (including the Isle of Man and the Channel Islands) for a total of six months or more between January 1980 and December 1996. The measure resulted in ten percent of New Zealand's active blood donors at the time becoming ineligible to donate blood. In 2003, the NZBS further extended restrictions to preclude permanently donors having had received a blood transfusion in the United Kingdom since January 1980, and in April 2006, restrictions were further extended to include the<space/><link><target>Republic of Ireland</target></link><space/>and<space/><link><target>France</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.nzblood.co.nz/content/download/620/3988/file/CJD%20Information%20Leaflet%20111I077.pdf<space/></arg><arg name="title"><space/>CJD (Creutzfeldt-Jakob Disease) - Information for blood donors<space/></arg><arg name="publisher"><space/>New Zealand Blood Service<space/></arg><arg name="accessdate"><space/>20 July 2012</arg></template></extension></paragraph><paragraph>Similar regulations are in place in Germany, where anyone having spent six months or more living in the UK between January 1980 and December 1996 is permanently banned from donating blood.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Permanent exclusion criteria
<space/></arg><arg name="url"><space/>http://www.blutspendehamburg.de/blutspender-gesucht/ausschluss
<space/></arg><arg name="publisher"><space/>Blutspendedienst Hamburg
<space/></arg><arg name="language"><space/>German
<space/></arg><arg name="accessdate"><space/>2009-06-20
</arg></template></extension></paragraph><paragraph>In<space/><link><target>Canada</target></link>, individuals are not eligible to donate blood or plasma if they have spent a cumulative total of three months in the United Kingdom or France from January 1, 1980, to December 31, 1996. They are also ineligible if they have spent a cumulative total of five years or more in Western Europe outside the U.K. or France since 1980, or if they have had a blood transfusion in the U.K., France or Western Europe since 1980.<extension extension_name='ref' name="Canada-IndefiniteDeferrals"><template><target>cite web</target><arg name="title">Indefinite Deferrals
<space/></arg><arg name="url">http://www.blood.ca/centreapps/internet/uw_v502_mainengine.nsf/page/Indefinite%20Deferral?OpenDocument
<space/></arg><arg name="website">Canadian Blood Services
<space/></arg><arg name="accessdate">25 June 2014
</arg></template></extension></paragraph><paragraph>The Association of Blood Donors of Denmark precludes potential donors having spent a cumulative time of at least 12 months in the United Kingdom between 1 January 1980 and 31 December 1996.</paragraph><paragraph>The Swiss Blutspendedienst SRK precludes potential donors having spent a cumulative time of at least six months in the<space/><link><target>United Kingdom</target></link><space/>between 1 January 1980 and 31 December 1996.</paragraph><paragraph>In<space/><link><target>Poland</target></link>, anyone having spent cumulatively six months or longer between 1 January 1980 and 31 December 1996 in the UK,<space/><link><target>Ireland</target></link>, or France is permanently barred from donating.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Permanent exclusion criteria / Dyskwalifikacja stała
<space/></arg><arg name="url"><space/>http://www.rckik-warszawa.com.pl/dlakrwio_ds.html
<space/></arg><arg name="publisher"><space/>RCKiK Warszawa
<space/></arg><arg name="language"><space/>Polish
<space/></arg><arg name="accessdate"><space/>2010-03-03
</arg></template><space/><template><target>Dead link</target><arg name="date">October 2010</arg><arg name="bot">H3llBot</arg></template></extension></paragraph><paragraph>In the<space/><link><target>Czech Republic</target></link>, anyone having spent more than six months in the<space/><link><target>UK</target></link><space/>or<space/><link><target>France</target></link><space/>between the years 1980 and 1996 or received transfusion in the UK after the year 1980 is not allowed to donate blood.<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Blood donor guidance / Poučení dárce krve
<space/></arg><arg name="url"><space/>http://www.fnkv.cz/soubory/pouceni-darce-krve-2007.doc
<space/></arg><arg name="publisher"><space/>Fakultní nemocnice Královské Vinohrady
<space/></arg><arg name="language"><space/>Czech
<space/></arg><arg name="accessdate"><space/>2010-03-20

In South Korea, anyone having spent more than three months in the [[UK]] after 1997, or more than a month between 1980 and 1996 is banned from donating blood. 
</arg></template></extension></paragraph><heading level='3'>Sperm donor restrictions</heading><paragraph>In the U.S., the FDA has banned import of any<space/><link><target>sperm donation</target><part>donor sperm</part></link>, motivated by a risk of Creutzfeldt&amp;ndash;Jakob disease, inhibiting the once popular<extension extension_name='ref' name="Stein"><template><target>cite news</target><arg name="last"><space/>Stein<space/></arg><arg name="first"><space/>Rob<space/></arg><arg name="title">Mad Cow Rules Hit Sperm Banks' Patrons<space/></arg><arg name="work">washingtonpost.com<space/></arg><arg name="publisher">The Washington Post Company<space/></arg><arg name="date"><space/>August 13, 2008<space/></arg><arg name="url">http://www.washingtonpost.com/wp-dyn/content/article/2008/08/12/AR2008081203131.html<space/></arg><arg name="accessdate"><space/>2008-10-04<space/></arg></template></extension><space/>import of<space/><link><target>Scandinavia</target><trail>n</trail></link><space/>sperm. The risk, however, is not known, since<space/><link><target>artificial insemination</target></link><space/>has not been studied as a route of transmission.<extension extension_name='ref' name="kotler"><template><target>cite news</target><arg name="title"><space/>The God of Sperm
<space/></arg><arg name="first"><space/>Steven
<space/></arg><arg name="last"><space/>Kotler
<space/></arg><arg name="url"><space/>http://www.laweekly.com/2007-09-27/news/the-god-of-sperm/
<space/></arg><arg name="publisher"><space/>LA Weekly
<space/></arg><arg name="date"><space/>2007-09-27
<space/></arg><arg name="accessdate"><space/>2009-06-20
<space/></arg></template></extension></paragraph><heading level='2'>Diagnosis</heading><paragraph>The diagnosis of CJD is suspected when there are typical clinical symptoms and signs such as rapidly progressing dementia with startle<space/><link><target>myoclonus</target></link>.<extension extension_name='ref'><template><target>cite book</target><arg name="last">Sattar</arg><arg name="first">Hussain A.<space/></arg><arg name="title">Fundamentals of Pathology</arg><arg name="accessdate">3 September 2014</arg><arg name="publisher">Pathoma LLC.</arg><arg name="location">Chicago<space/></arg><arg name="page">187<space/></arg></template></extension><space/>Further investigation can then be performed to support the diagnosis including</paragraph><list type='bullet'><listitem><link><target>Electroencephalography</target></link>&amp;mdash; often has characteristic generalized periodic sharp wave pattern (~80% of pts by 6 months)<template><target>mcn</target><arg name="date">May 2015</arg></template></listitem><listitem><link><target>Cerebrospinal fluid</target></link><space/>analysis for<space/><link><target>14-3-3 protein</target></link></listitem><listitem><link><target>MRI</target></link><space/>of the brain&amp;mdash;often shows high signal intensity in the caudate nucleus and putamen bilaterally on T2-weighted images.</listitem><listitem>Research in 2010 and 2011 identified a possible blood test for CJD. The test attempts to identify the prion responsible for the disease. However, it has not yet been demonstrated if it is able to detect the prions in early stages of the disease.<extension extension_name='ref' name="MSNBC Rettner"><template><target>cite news</target><arg name="title"><space/>Blood test may screen for human form of mad cow<space/></arg><arg name="author">Rachael Rettner<space/></arg><arg name="url"><space/>http://www.msnbc.msn.com/id/41406612/ns/health-infectious_diseases/<space/></arg><arg name="publisher"><space/>[[MSNBC]]<space/></arg><arg name="date"><space/>2011-02-03<space/></arg><arg name="accessdate"><space/>2011-02-09</arg></template></extension></listitem></list><paragraph>Diffusion Weighted Imaging (DWI) images are the most sensitive. In about 24% of cases DWI shows only cortical hyperintensity; in 68%, cortical and subcortical abnormalities; and in 5%, only subcortical anomalies.<extension extension_name='ref'><template><target>cite journal</target><arg name="last"><space/>Young</arg><arg name="first"><space/>Geoffrey S.</arg><arg name="title">Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Imaging in Creutzfeldt–Jakob Disease: High Sensitivity and Specificity for Diagnosis</arg><arg name="journal">[[American Journal of Neuroradiology]]</arg><arg name="volume"><space/>26</arg><arg name="pages">1551–1562</arg><arg name="date">June–July 2005</arg><arg name="publisher">American Society of Neuroradiology</arg><arg name="url">http://www.ajnr.org/cgi/content/full/26/6/1551</arg><arg name="accessdate"><space/>2007-10-30</arg><arg name="pmid">15956529</arg><arg name="issue"><space/>6<space/></arg><arg name="author2">Michael D. Geschwind<space/></arg><arg name="author3">Nancy J. Fischbein<space/></arg><arg name="author4">Jennifer L. Martindale<space/></arg><arg name="author5">Roland G. Henry<space/></arg><arg name="author6">Songling Liu<space/></arg><arg name="author7">Ying Lu<space/></arg><arg name="author8">Stephen Wong<space/></arg><arg name="author9">Hong Liu<space/></arg><arg name="author10">Bruce L. Miller<space/></arg><arg name="author11">William P. Dillon</arg></template></extension>The involvement of the thalamus can be found in sCJD, is even stronger and constant in vCJD.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Tschampa<space/></arg><arg name="first">Henriette J.<space/></arg><arg name="authorlink"><space/></arg><arg name="title">Thalamic Involvement in Sporadic Creutzfeldt–Jakob Disease: A Diffusion-Weighted MR Imaging Study<space/></arg><arg name="journal">American Journal of Neuroradiology<space/></arg><arg name="volume">24<space/></arg><arg name="pages">908–915<space/></arg><arg name="publisher">American Society of Neuroradiology<space/></arg><arg name="date">1 May 2003</arg><arg name="url">http://www.ajnr.org/cgi/content/full/24/5/908<space/></arg><arg name="accessdate"><space/>2007-10-30<space/></arg><arg name="pmid">12748093<space/></arg><arg name="issue">5<space/></arg><arg name="author2">M<space/></arg><arg name="author3">F<space/></arg><arg name="author4">P<space/></arg><arg name="author5">S<space/></arg><arg name="author6">U</arg></template></extension></paragraph><paragraph>Clinical testing for CJD has always been an issue. Diagnosis has been based mostly on clinical and physical examination of symptoms. In recent years, studies have shown that the tumour marker<space/><link><target>Neuron-specific enolase</target></link><space/>(NSE) is often elevated in CJD cases, however its diagnostic utility is seen primarily when combined with a test for the<space/><link><target>14-3-3 protein</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1212/01.wnl.0000230159.67128.00<space/></arg><arg name="title">CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease<space/></arg><arg name="author">Sanchez–Juan, P., Green, A., Ladogana, A.</arg><arg name="year">2006<space/></arg><arg name="journal">Neurology<space/></arg><arg name="volume">67<space/></arg><arg name="issue">4<space/></arg><arg name="pages">637–643<space/></arg><arg name="pmid">16924018</arg><arg name="display-authors">etal</arg></template></extension><space/><template><target>As of</target><arg>2010</arg></template>, screening tests to identify infected asymptomatic individuals, such as blood donors, are not yet available, though methods have been proposed and evaluated.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1111/j.1537-2995.2010.02731.x</arg><arg name="title">A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K</arg><arg name="author">Tattum, M. H., Jones, S., Pal, S., Khalili-Shirazi, A., Collinge, J., Jackson, G.</arg><arg name="date">December 2010</arg><arg name="journal">Transfusion</arg><arg name="volume">50</arg><arg name="pages">2619–2627</arg><arg name="publisher">[[AABB]]</arg><arg name="issue">12</arg><arg name="pmid">20561299</arg></template></extension></paragraph><paragraph>In 2010, a team from New York described detection of PrP<xhtml:sup>Sc</xhtml:sup><space/>even when initially present at only one part in one hundred billion (10<xhtml:sup>11</xhtml:sup>) in brain tissue. The method combines amplification with a novel technology called<space/><link><target>surround optical fiber immunoassay</target></link><space/>(SOFIA) and some specific antibodies against PrP<xhtml:sup>Sc</xhtml:sup>. After amplifying and then concentrating any PrP<xhtml:sup>Sc</xhtml:sup>, the samples are labelled with a fluorescent dye using an antibody for specificity and then finally loaded into a micro-capillary tube. This tube is placed in a specially constructed apparatus so that it is totally surrounded by optical fibres to capture all light emitted once the dye is excited using a laser. The technique allowed detection of PrP<xhtml:sup>Sc</xhtml:sup><space/>after many fewer cycles of conversion than others have achieved, substantially reducing the possibility of artefacts, as well as speeding up the assay. The researchers also tested their method on blood samples from apparently healthy sheep that went on to develop scrapie. The animals brains were analysed once any symptoms became apparent. The researchers could therefore compare results from brain tissue and blood taken once the animals exhibited symptoms of the diseases, with blood obtained earlier in the animals lives, and from uninfected animals. The results showed very clearly that PrP<xhtml:sup>Sc</xhtml:sup><space/>could be detected in the blood of animals long before the symptoms appeared. After further development and testing, this method could be of great value in surveillance as a blood or urine-based screening test for CJD.<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Detecting Prions in Blood<space/></arg><arg name="journal">Microbiology Today<space/></arg><arg name="pages">195<space/></arg><arg name="date">August 2010<space/></arg><arg name="url"><space/>https://www.sgm.ac.uk/pubs/micro_today/pdf/081010.pdf<space/></arg><arg name="accessdate">2011-08-21</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.bionosis.com/news/Bionosis%20PrioNet%20Poster.pdf<space/></arg><arg name="title">SOFIA: An Assay Platform for Ultrasensitive Detection of PrP<sup>Sc</sup><space/>in Brain and Blood<space/></arg><arg name="publisher"><space/>[[SUNY Downstate Medical Center]]<space/></arg><arg name="authorlink">Rubenstein, R., et al.<space/></arg><arg name="accessdate">2011-08-19</arg></template></extension><space/>In 2014 a human study showed a nasal brushing method that can accurately detect PrP in the olfactory epithelial of CJD patients. .<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1056/NEJMoa1315200</arg><arg name="title">A test for Creutzfeldt-Jakob disease using nasal brushings.</arg><arg name="author">Orrú, C.D., Bongianni, M., Tonoli, G., Ferrari, S., Hughson, A.G., Groveman, B.R., Fiorini, M., Pocchiari, M., Monaco, S., Caughey, B., Zanusso, G.<space/></arg><arg name="date">August 2014</arg><arg name="journal">New England Journal of Medicine</arg><arg name="volume">371</arg><arg name="pages">530–9</arg><arg name="issue">6</arg><arg name="pmid">25099576</arg></template></extension>This finding creates new opportunities for minimally invasive detection of CJD.</paragraph><paragraph>In one-third of patients with sporadic CJD, deposits of &quot;prion protein (scrapie),&quot;<space/><link><target>PrpSc</target><part>PrP<xhtml:sup>Sc</xhtml:sup></part></link>, can be found in the<space/><link><target>skeletal muscle</target></link><space/>and/or the<space/><link><target>spleen</target></link>.<template><target>Citation needed</target><arg name="date">August 2008</arg></template><space/>Diagnosis of vCJD can be supported by biopsy of the tonsils, which harbour significant amounts of PrPSc; however,<space/><link><target>biopsy</target></link><space/>of brain tissue is the definitive diagnostic test for all other forms of prion disease. Due to its invasiveness, biopsy will not be done if clinical suspicion is sufficiently high or low. A negative biopsy does not rule out CJD, since it may predominate in a specific part of the brain.<extension extension_name='ref' name="ReferenceA">Sternberg's Diagnostic Surgical Pathology, 5th edition.</extension></paragraph><paragraph><link><target>Image:SpongiformChangeCJD.jpg</target><part>thumbnail</part><part>right</part><part>Spongiform change in CJD</part></link>The classic<space/><link><target>histologic</target></link><space/>appearance is spongiform change in the gray matter: the presence of many round vacuoles from one to 50 micrometres in the<space/><link><target>neuropil</target></link>, in all six cortical layers in the cerebral cortex or with diffuse involvement of the cerebellar molecular layer. These vacuoles appear glassy or eosinophilic and may coalesce. Neuronal loss and gliosis are also seen.<extension extension_name='ref'><template><target>cite web</target><arg name="title">CNS Degenerative Diseases</arg><arg name="url">http://library.med.utah.edu/WebPath/TUTORIAL/CNS/CNSDG.html</arg></template></extension><space/>Plaques of amyloid-like material can be seen in the neocortex in new-variant CJD.</paragraph><paragraph>However,<space/><link><target>vacuolization</target></link><space/>can be seen in other disease states. Diffuse cortical vacuolization occurs in<space/><link><target>Alzheimer's</target></link>, and superficial cortical vacuolization occurs in<space/><link><target>ischemia</target></link><space/>and<space/><link><target>frontotemporal dementia</target></link>. These vacuoles appear clear and punched-out. Larger vacuoles encircling neurons, vessels, and<space/><link><target>glia</target></link><space/>are a possible processing artifact.<extension extension_name='ref' name="ReferenceA"></extension></paragraph><list type='bullet'><listitem>Clinical and Pathologic Characteristics:<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Belay ED, Schonberger LB<space/></arg><arg name="title">Variant Creutzfeldt–Jakob disease and bovine spongiform encephalopathy<space/></arg><arg name="journal">Clin. Lab. Med.<space/></arg><arg name="volume">22<space/></arg><arg name="issue">4<space/></arg><arg name="pages">849–62, v–vi<space/></arg><arg name="year">2002<space/></arg><arg name="pmid">12489284<space/></arg><arg name="doi">10.1016/S0272-2712(02)00024-0</arg></template></extension></listitem></list><table class="wikitable" border="1"><tablerow><tablehead>Characteristic</tablehead><tablehead>Classic CJD</tablehead><tablehead>Variant CJD</tablehead></tablerow><tablerow><tablecell>Median age at death</tablecell><tablecell>68 years</tablecell><tablecell>28 years</tablecell></tablerow><tablerow><tablecell>Median duration of illness</tablecell><tablecell>45 months</tablecell><tablecell>1314 months</tablecell></tablerow><tablerow><tablecell>Clinical signs and symptoms</tablecell><tablecell>Dementia; early neurologic signs</tablecell><tablecell>Prominent psychiatric/behavioral symptoms; painful<space/><link><target>dysesthesias</target></link>;delayed neurologic signs</tablecell></tablerow><tablerow><tablecell>Periodic sharp waves on<space/><link><target>electroencephalogram</target></link></tablecell><tablecell>Often present</tablecell><tablecell>Often absent</tablecell></tablerow><tablerow><tablecell>Signal hyperintensity in the<space/><link><target>caudate nucleus</target></link><space/>and<space/><link><target>putamen</target></link><space/>on diffusion-weighted and<space/><link><target>FLAIR MRI</target></link></tablecell><tablecell>Often present</tablecell><tablecell>Often absent</tablecell></tablerow><tablerow><tablecell><link><target>Pulvinar nuclei</target><part>Pulvinar</part></link><space/>sign-bilateral high signal intensities on axial<space/><link><target>Magnetic resonance imaging#Fluid attenuated inversion recovery .28FLAIR.29</target><part>fluid attenuated inversion recovery</part></link><space/>(FLAIR) MRI. Also posterior thalami involvement on sagittal T2 sequences</tablecell><tablecell>Not reported</tablecell><tablecell>Present in &amp;gt;75% of cases</tablecell></tablerow><tablerow><tablecell><link><target>Immunohistochemical staining</target><part>Immunohistochemical analysis</part></link><space/>of brain tissue</tablecell><tablecell>Variable accumulation.</tablecell><tablecell>Marked accumulation of protease-resistant prion protein</tablecell></tablerow><tablerow><tablecell>Presence of agent in<space/><link><target>lymphoid</target></link><space/>tissue</tablecell><tablecell>Not readily detected</tablecell><tablecell>Readily detected</tablecell></tablerow><tablerow><tablecell>Increased<space/><link><target>glycoform</target></link><space/>ratio on<space/><link><target>immunoblot</target></link><space/>analysis ofprotease-resistant prion protein</tablecell><tablecell>Not reported</tablecell><tablecell>Marked accumulation of protease-resistant prion protein</tablecell></tablerow><tablerow><tablecell>Presence of amyloid plaques in brain tissue</tablecell><tablecell>May be present</tablecell><tablecell>May be present</tablecell></tablerow></table><list type='bullet'><listitem>An abnormal signal in the posterior thalamus on T2- and diffusion-weighted images and fluid-attenuated inversion recovery sequences on brain magnetic resonance imaging (MRI); in the appropriate clinical context, this signal is highly specific for vCJD. (Source: CDC)</listitem></list><heading level='2'>Treatment</heading><paragraph><template><target>As of</target><arg>2015</arg></template>, no generally accepted treatment for CJD exists; the disease is invariably fatal and research continues. An experimental treatment was given to a Northern<space/><link><target>Irish people</target><part>Irish</part></link><space/>teenager, Jonathan Simms, beginning in January 2003.<extension extension_name='ref'><template><target>cite news</target><arg name="title">Teenager with vCJD 'stable''<space/></arg><arg name="publisher">BBC News<space/></arg><arg name="date">13 December 2004<space/></arg><arg name="url">http://news.bbc.co.uk/2/hi/uk_news/northern_ireland/4092363.stm<space/></arg><arg name="accessdate">2007-01-01<space/></arg><arg name="location">London</arg></template></extension><space/>The medication, called<space/><link><target>pentosan polysulphate</target></link><space/>(PPS) and used to treat<space/><link><target>interstitial cystitis</target></link>, is infused into the patient's<space/><link><target>ventricular system</target><part>lateral ventricle</part></link><space/>within the brain. PPS does not seem to stop the disease from progressing, and both brain function and tissue continue to be lost. However, the treatment is alleged to slow the progression of the otherwise untreatable disease, and may have contributed to the longer than expected survival of the seven patients studied.<extension extension_name='ref'><template><target>cite news</target><arg name="last">Bone<space/></arg><arg name="first">Ian<space/></arg><arg name="title">Intraventricular Pentosan Polysulphate in Human Prion Diseases: A study of Experience in the United Kingdom<space/></arg><arg name="publisher">Medical Research Council<space/></arg><arg name="date">12 July 2006<space/></arg><arg name="url">http://www.bbc.co.uk/news/uk-northern-ireland-12667709<space/></arg><arg name="accessdate">2012-11-09</arg></template></extension><space/>Simms died in 2011.<extension extension_name='ref'><template><target>cite news</target><arg name="title">Belfast man with vCJD dies after long battle<space/></arg><arg name="publisher">BBC News<space/></arg><arg name="date">7 March 2011<space/></arg><arg name="url"><space/>http://bbc.co.uk/news/uk-northern-ireland-12667709<space/></arg><arg name="accessdate">2013-04-11<space/></arg><arg name="location">London</arg></template></extension><space/>The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that pentosan polysulphate is an effective treatment and suggests that further research in animal models is appropriate.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Use of Pentosan Polysulphate in the treatment of, or prevention of, vCJD<space/></arg><arg name="url">http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/CJD/CJDgeneralinformation/DH_4031039<space/></arg><arg name="publisher">Department of Health:CJD Therapy Advisory Group<space/></arg><arg name="accessdate">2007-10-30</arg></template></extension><space/>A 2007 review of the treatment of 26 patients with PPS finds no proof of efficacy because of the lack of accepted objective criteria.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K<space/></arg><arg name="title">Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?<space/></arg><arg name="journal">Expert opinion on biological therapy<space/></arg><arg name="volume">7<space/></arg><arg name="issue">5<space/></arg><arg name="pages">713–26<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17477808<space/></arg><arg name="doi">10.1517/14712598.7.5.713</arg></template></extension></paragraph><paragraph>Scientists have investigated using<space/><link><target>RNA interference</target></link><space/>to slow the progression of<space/><link><target>scrapie</target></link><space/>in<space/><link><target>mice</target></link>. The RNA blocks production of the protein that the CJD process transforms into prions. This research is unlikely to lead to a human therapy for many years.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Pfeifer A, Eigenbrod S, Al-Khadra S
</arg><arg name="title"><space/>Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice
</arg><arg name="journal"><space/>The Journal of Clinical Investigation
</arg><arg name="volume"><space/>116
</arg><arg name="issue"><space/>12
</arg><arg name="pages"><space/>3204–10
</arg><arg name="date">December 2006
</arg><arg name="pmid"><space/>17143329
</arg><arg name="pmc"><space/>1679709
</arg><arg name="doi"><space/>10.1172/JCI29236
</arg><arg name="laysummary"><space/>http://news.bbc.co.uk/1/hi/health/6198072.stm
</arg><arg name="laysource"><space/>BBC News
</arg><arg name="laydate"><space/>2006-12-04
</arg></template></extension></paragraph><paragraph>Both<space/><link><target>amphotericin B</target></link><space/>and<space/><link><target>doxorubicin</target></link><space/>have been investigated as potentially effective against CJD, but as yet there is no strong evidence that either drug is effective in stopping the disease. Further study has been taken with other medical drugs, but none are effective. However, drugs to reduce suffering do exist, and include<space/><link><target>valproate</target></link>, an anticonvulsant agent,<space/><link><target>clonazepam</target></link><space/>and<space/><link><target>benzodiazepine</target></link>, to reduce muscle jerks.<extension extension_name='ref' name="Gambetti"></extension></paragraph><paragraph>Scientists from the<space/><link><target>University of California, San Francisco</target></link><space/>are currently running a<space/><link type='external' href='http://memory.ucsf.edu/cjd/research/current/quinacrine'>treatment trial for sporadic CJD</link><space/>using<space/><link><target>quinacrine</target></link>, a medicine originally created for<space/><link><target>malaria</target></link>. Pilot studies showed quinacrine permanently cleared abnormal prion proteins from cell cultures, but results have not yet been published on their clinical study. The efficacy of quinacrine was also assessed in a rigorous clinical trial in the UK and the results were published in Lancet Neurology,<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Collinge</arg><arg name="first">J</arg><arg name="author2">Gorham, M<space/></arg><arg name="author3">Hudson, F<space/></arg><arg name="author4">Kennedy, A<space/></arg><arg name="author5">Keogh, G<space/></arg><arg name="author6">Pal, S<space/></arg><arg name="author7">Rossor, M<space/></arg><arg name="author8">Rudge, P<space/></arg><arg name="author9">Siddique, D<space/></arg><arg name="author10">Spyer, M<space/></arg><arg name="author11">Thomas, D<space/></arg><arg name="author12">Walker, S<space/></arg><arg name="author13">Webb, T<space/></arg><arg name="author14">Wroe, S<space/></arg><arg name="author15">Darbyshire, J<space/></arg><arg name="title">Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial</arg><arg name="journal">Lancet neurology</arg><arg name="date">April 2009</arg><arg name="volume">8</arg><arg name="issue">4</arg><arg name="pages">334–44</arg><arg name="pmid">19278902</arg><arg name="doi">10.1016/S1474-4422(09)70049-3</arg><arg name="pmc">2660392</arg></template></extension><space/>and concluded that quinacrine had no measurable effect on the clinical course of CJD.</paragraph><paragraph>In a 2013 paper published in the Proceedings of the National Academy of Sciences, scientists from The<space/><link><target>Scripps Research Institute</target></link><space/>reported that<space/><link><target>Astemizole</target></link>, a medication approved for human use, has been found to have anti-prion activity and may lead to a treatment for CreutzfeldtJakob disease.<extension extension_name='ref' name="Karapetyan2013"><template><target>cite journal</target><arg name="last"><space/>Karapetyan<space/></arg><arg name="first"><space/>Yervand Eduard<space/></arg><arg name="author2">Gian Franco Sferrazza<space/></arg><arg name="author3">Minghai Zhou<space/></arg><arg name="author4">Gregory Ottenberg<space/></arg><arg name="author5">Timothy Spicer<space/></arg><arg name="author6">Peter Chase<space/></arg><arg name="author7">Mohammad Fallahi<space/></arg><arg name="author8">Peter Hodder<space/></arg><arg name="author9">Charles Weissmann<space/></arg><arg name="author10">Corinne Ida Lasmézas<space/></arg><arg name="title"><space/>Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents<space/></arg><arg name="journal"><space/>Proceedings of the National Academy of Sciences<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="url"><space/>http://www.pnas.org/content/early/2013/03/29/1303510110.abstract<space/></arg><arg name="doi"><space/>10.1073/pnas.1303510110<space/></arg><arg name="laysummary"><space/>http://www.scripps.edu/news/press/2013/20130403lasmezas.html<space/></arg><arg name="laysource"><space/>Scripps Research Institute News Release<space/></arg><arg name="laydate"><space/>April 3, 2013</arg><arg name="volume"><space/>110</arg><arg name="issue"><space/>17</arg><arg name="pages"><space/>7044–7049</arg></template></extension></paragraph><heading level='2'>Epidemiology</heading><paragraph><link><target>File:Global mad cow cases map.PNG</target><part>thumb</part><part>450px</part><part>Dark green areas are countries that have confirmed human cases of variant CreutzfeldtJakob disease and light green are countries that have bovine spongiform encephalopathy cases.</part></link>Although CJD is the most common human<space/><link><target>prion disease</target></link>, it is still rare, occurring in about one out of every one million people every year. It usually affects people aged 4575, most commonly appearing in people between the ages of 6065. The exception to this is the more recently recognised 'variant' CJD (vCJD), which occurs in younger people.</paragraph><paragraph><link><target>Centers for Disease Control and Prevention</target><part>CDC</part></link><space/>monitors the occurrence of CJD in the United States through periodic reviews of national mortality data. According to the<space/><link><target>Centers for Disease Control and Prevention</target><part>CDC</part></link>:</paragraph><list type='bullet'><listitem>CJD occurs worldwide at a rate of about 1 case per million population per year.</listitem><listitem>On the basis of mortality surveillance from 1979 to 1994, the annual<space/><link><target>incidence (epidemiology)</target><part>incidence</part></link><space/>of CJD remained stable at approximately 1 case per<space/><link><target>million</target></link><space/>persons in the United States.</listitem><listitem>In the United States, CJD deaths among persons younger than 30 years of age are extremely rare (fewer than five deaths per<space/><link><target>1000000000 (number)</target><part>billion</part></link><space/>per year<extension extension_name='ref' name="CDC1"></extension><extension extension_name='ref' name="VCJD1"><template><target>cite web</target><arg name="title"><space/>vCJD (Variant Creutzfeldt–Jakob Disease)
<space/></arg><arg name="url"><space/>http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet_nvcjd.htm
<space/></arg><arg name="publisher"><space/>Centers for Disease Control and Prevention
<space/></arg><arg name="date"><space/>2007-01-04
<space/></arg><arg name="accessdate"><space/>2009-06-20
</arg></template></extension>).</listitem><listitem>The disease is found most frequently in patients 5565 years of age, but cases can occur in people older than 90 years and younger than 55 years of age.</listitem><listitem>In more than 85% of cases, the duration of CJD is less than 1 year (median: four months) after onset of symptoms.<extension extension_name='ref' name="CDC1"></extension><extension extension_name='ref' name="VCJD1"></extension></listitem></list><heading level='3'>Additional concerns</heading><paragraph>In<space/><italics><link><target>The Lancet</target></link></italics><space/>(June 2006), a University College London team suggested that it may take more than 50 years for vCJD to develop, from their studies of<space/><link><target>Kuru (disease)</target><part>kuru</part></link>, a similar disease in<space/><link><target>Papua New Guinea</target></link>.<extension extension_name='ref' name="titleForbes.com"></extension><space/>The reasoning behind the claim is that kuru was possibly transmitted through<space/><link><target>cannibalism</target></link><space/>in Papua New Guinea when family members would eat the body of a dead relative as a sign of<space/><link><target>mourning</target></link>. In the 1950s, cannibalism was banned in Papua New Guinea.<extension extension_name='ref' name="Diamond"><template><target>cite journal</target><arg name="last"><space/>Diamond
</arg><arg name="first"><space/>JM
</arg><arg name="date">7 September 2000
</arg><arg name="title"><space/>Archaeology: Talk of cannibalism
</arg><arg name="journal"><space/>Nature
</arg><arg name="volume"><space/>407
</arg><arg name="issue"><space/>25–26
</arg><arg name="doi"><space/>10.1038/35024175
</arg><arg name="pages"><space/>25–6
</arg><arg name="pmid">10993054
</arg></template></extension>In the late 20th century, however, kuru reached epidemic proportions in certain Papua New Guinean communities, therefore suggesting that vCJD may also have a similar<space/><link><target>incubation period</target></link><space/>of 20 to 50 years. A critique to this theory is that while mortuary cannibalism was banned in Papua New Guinea in the 1950s, that does not necessarily mean that the practice ended. 15 years later<space/><link><target>Jared Diamond</target></link><space/>was informed by<space/><link><target>Papuans</target></link><space/>that the practice continued.<extension extension_name='ref' name="Diamond"></extension><space/>Kuru may have passed to the<space/><link><target>Fore people</target></link><space/>through the preparation of the dead body for burial. Some cite this as substantiation for the belief that cannibalism transmits some metaphysical part of the meal to the diner.</paragraph><paragraph>These researchers noticed a genetic variation in some kuru patients that has been known to promote long<space/><link><target>incubation period</target><trail>s</trail></link>. They have also proposed that individuals having contracted CJD in the early 1990s represent a distinct genetic subpopulation, with unusually short incubation periods for<space/><link><target>bovine spongiform encephalopathy</target></link><space/>(BSE). This means that there may be many more vCJD patients with longer incubation periods, which may surface many years later.<extension extension_name='ref' name="titleForbes.com"><template><target>cite journal</target><arg name="author"><space/>Collinge J, Whitfield J, McKintosh E
</arg><arg name="title"><space/>Kuru in the 21st century—an acquired human prion disease with very long incubation periods
</arg><arg name="journal"><space/>Lancet
</arg><arg name="volume"><space/>367
</arg><arg name="issue"><space/>9528
</arg><arg name="pages"><space/>2068–74
</arg><arg name="date">June 2006
</arg><arg name="pmid"><space/>16798390
</arg><arg name="doi"><space/>10.1016/S0140-6736(06)68930-7
</arg></template></extension></paragraph><paragraph>In 1997, a number of people from<space/><link><target>Kentucky</target></link>, USA developed CJD. It was discovered that all the victims had consumed<space/><link><target>squirrel</target></link><space/>brains, although a coincidental relationship between the disease and this dietary practice may have been involved.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Berger JR, Waisman E, Weisman B
</arg><arg name="title"><space/>Creutzfeldt–Jakob disease and eating squirrel brains
</arg><arg name="journal"><space/>Lancet
</arg><arg name="volume"><space/>350
</arg><arg name="issue"><space/>9078
</arg><arg name="pages"><space/>642
</arg><arg name="date">August 1997
</arg><arg name="pmid"><space/>9288058
</arg><arg name="doi"><space/>10.1016/S0140-6736(05)63333-8
</arg></template></extension>In 2008,<space/><link><target>UK</target></link><space/>scientists expressed concern over the possibility of a second wave of human cases due to the wide exposure and long incubation of some cases of vCJD.<extension extension_name='ref'><link type='external' href='http://www.guardian.co.uk/uk/2008/aug/03/bse.medicalresearch'>Warning over second wave of CJD cases</link></extension></paragraph><heading level='2'>History</heading><paragraph>The disease was first described by German<space/><link><target>neurologist</target></link><space/><link><target>Hans Gerhard Creutzfeldt</target></link><space/>in 1920 and shortly afterward by<space/><link><target>Alfons Maria Jakob</target></link>, giving it the name Creutzfeldt&amp;ndash;Jakob. Some of the clinical findings described in their first papers do not match current criteria for Creutzfeldt&amp;ndash;Jakob disease, and it has been speculated that at least two of the patients in initial studies were suffering from a different ailment.<template><target>Citation needed</target><arg name="date">February 2009</arg></template><space/>An early description of familial CJD stems from the German psychiatrist and neurologist<space/><link><target>Friedrich Meggendorfer</target></link><space/>(18801953).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Meggendorfer F<space/></arg><arg name="year"><space/>1930<space/></arg><arg name="title"><space/>Klinische und genealogische Beobachtungen bei einem Fall von spastischer Pseudokosklerose Jakobs<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Z Neurol Psychiatry<space/></arg><arg name="volume"><space/>128<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>337–41<space/></arg><arg name="doi">10.1007/bf02864269</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="pmid"><space/>14522861<space/></arg><arg name="volume">66<space/></arg><arg name="title">Sporadic and familial CJD: classification and characterisation<space/></arg><arg name="year">2003<space/></arg><arg name="author">Gambetti P, Kong Q, Zou W, Parchi P, Chen SG<space/></arg><arg name="journal">Br. Med. Bull.<space/></arg><arg name="pages">213–39<space/></arg><arg name="doi"><space/>10.1093/bmb/66.1.213</arg></template></extension><space/>A study published in 1997 counted more than 100 cases worldwide of transmissible CJD and new cases continued to appear at the time.<extension extension_name='ref' name="ricketts"><link type='external' href='http://wwwnc.cdc.gov/eid/article/3/2/97-0208_article.htm'>Emerging Infectious Diseases: &quot;Is Creutzfeldt-Jakob Disease Transmitted in Blood?&quot; (Ricketts et al) vol 3, Jun 1997</link></extension></paragraph><paragraph>The first report of suspected<space/><link><target>iatrogenic</target></link><space/>CJD was published in 1974. Animal experiments showed that corneas of infected animals could transmit CJD, and the causative agent spreads along visual pathways. A second case of CJD associated with a corneal transplant was reported without details. In 1977, CJD transmission caused by silver electrodes previously used in the brain of a person with CJD was first reported. Transmission occurred despite decontamination of the electrodes with ethanol and formaldehyde. Retrospective studies identified four other cases likely of similar cause. The rate of transmission from a single contaminated instrument is unknown, although it is not 100%. In some cases the exposure occurred weeks after the instruments were used on a person with CJD.<extension extension_name='ref' name="ricketts"></extension></paragraph><paragraph>A review article published in 1979 indicated that 25 dura mater cases had occurred by that date in Australia, Canada, Germany, Italy, Japan, New Zealand, Spain, the United Kingdom, and the United States.<extension extension_name='ref' name="ricketts"></extension></paragraph><paragraph>By 1985, a series of case reports in the United States showed that when injected, cadaver-extracted pituitary<space/><link><target>human growth hormone</target></link><space/>could transmit CJD to humans.<extension extension_name='ref' name="ricketts"></extension></paragraph><paragraph>In 1992 it was recognized that human<space/><link><target>gonadotropin</target></link><space/>administered by injection could also transmit CJD from person to person.<extension extension_name='ref' name="ricketts"></extension></paragraph><paragraph>In 2004, a report published by Edinburgh doctors in the<space/><italics><link><target>The Lancet</target><part>Lancet</part></link></italics><space/>medical journal demonstrated that vCJD was transmitted by<space/><link><target>blood transfusion</target></link>.<extension extension_name='ref' name="pmid15302196"></extension></paragraph><paragraph><link><target>Stanley B. Prusiner</target></link><space/>of the<space/><link><target>University of California, San Francisco</target></link><space/>(UCSF) was awarded the<space/><link><target>Nobel Prize in physiology or medicine</target></link><space/>in 1997 &quot;for his discovery of Prions - a new biological principle of infection&quot;.<extension extension_name='ref' name="Nobel"><template><target>cite web</target><arg name="url">http://www.nobelprize.org/nobel_prizes/medicine/laureates/1997/<space/></arg><arg name="title">The Nobel Prize in Physiology or Medicine 1997: Stanley B. Prusiner<space/></arg><arg name="publisher">NobelPrize.org<space/></arg><arg name="accessdate">2011-02-21</arg></template></extension><space/>For more than a decade,<space/><link><target>Yale University</target></link><space/><link><target>neuropathologist</target></link><space/><link><target>Laura Manuelidis</target></link><space/>had been challenging this explanation for the disease. In January 2007, she and her colleagues published an article in the<space/><italics><link><target>Proceedings of the National Academy of Science</target></link></italics><space/>and reported that they had found a<space/><link><target>virus</target></link>-like particle (but without finding<space/><link><target>nucleic acid</target><trail>s</trail></link>) in less than 10% of the cells in a<space/><link><target>scrapie</target></link>-infected cell line and in a mouse cell line infected by a human CJD agent.<extension extension_name='ref' name="Manuelidis2007"><template><target>cite journal</target><arg name="author"><space/>Manuelidis L, Yu ZX, Barquero N, Banquero N, Mullins B
</arg><arg name="title"><space/>Cells infected with scrapie and Creutzfeldt-Jakob disease agents produce intracellular 25-nm virus-like particles
</arg><arg name="journal"><space/>Proceedings of the National Academy of Sciences of the United States of America
</arg><arg name="volume"><space/>104
</arg><arg name="issue"><space/>6
</arg><arg name="pages"><space/>1965–70
</arg><arg name="date">February 2007
</arg><arg name="pmid"><space/>17267596
</arg><arg name="pmc"><space/>1794316
</arg><arg name="doi"><space/>10.1073/pnas.0610999104
</arg></template></extension></paragraph><heading level='3'>Australia</heading><paragraph>Four Australians had been reported with CJD following transfusion as of 1997.<extension extension_name='ref' name="ricketts"></extension><space/>There have been ten cases of healthcare-acquired CJD in Australia. They consist of five deaths following treatment with pituitary extract hormone for either infertility or short stature, with no further cases since 1991. The five other deaths were caused by dura grafting during brain surgery, where the covering of the brain was repaired. There have been no other known healthcare-acquired CJD deaths in Australia.<extension extension_name='ref'><link type='external' href='http://ideas.health.vic.gov.au/diseases/cjd-facts.asp'>Creutzfeldt-Jakob Disease (CJD) - the facts - Infectious Diseases Epidemiology &amp; Surveillance - Department of Health, Victoria, Australia</link></extension></paragraph><heading level='3'>New Zealand</heading><paragraph>A case was reported in 1989 in a 25-year-old man from New Zealand, who also received<space/><link><target>dura mater</target></link><space/>transplant.<extension extension_name='ref' name="ricketts"></extension><space/>Five New Zealanders have been confirmed to have died of the sporadic form of CreutzfeldtJakob disease (CJD) in 2012.<extension extension_name='ref'><link type='external' href='http://www.stuff.co.nz/national/health/7962582/'>Mad cow link in hunter's death | Stuff.co.nz</link></extension></paragraph><heading level='3'>United Kingdom</heading><paragraph><link><target>File:NCJDRSU-2014.png</target><part>thumb</part><part>220px</part><part>Deaths in the UK from Creutzfeldt-Jacob disease 1990-2014: while cases of vCJD have declined (green), reported cases of sporadic CJD continue to increase (blue)</part></link>Researchers believe one in 2,000 people in the UK is a carrier of the disease linked to eating contaminated beef (vCJD).<extension extension_name='ref'><template><target>cite news</target><arg name="url">http://www.bbc.co.uk/news/health-24525584<space/></arg><arg name="work">BBC News<space/></arg><arg name="title">Estimate doubled for vCJD carriers in UK<space/></arg><arg name="date">2013-10-15</arg></template></extension><space/>The survey provides the most robust prevalence measure to dateand identifies abnormal prion protein across a wider age group than found previously and in all genotypes, indicating &quot;infection&quot; may be relatively common. This new study examined over 32,000 anonymous appendix samples. Of these, 16 samples were positive for abnormal prion protein, indicating an overall prevalence of 493 per million population, or one in 2,000 people are likely to be carriers. No difference was seen in different birth cohorts (194160 and 196185), in both sexes, and there was no apparent difference in abnormal prion prevalence in three broad geographical areas. Genetic testing of the 16 positive samples revealed a higher proportion of valine homozygous (VV) genotype on the codon 129 of the gene encoding the prion protein (PRNP) compared with the general UK population. This also differs from the 177 patients with vCJD, all of whom to date have been methionine homozygous (MM) genotype. The concern is that individuals with this VV genotype may be susceptible to developing the condition over longer incubation periods, or they may not show any clinical signs of disease.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Gill</arg><arg name="first">Noel</arg><arg name="title">Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey</arg><arg name="url">http://www.bmj.com/cgi/doi/10.1136/bmj.f5675</arg><arg name="work">British Medical Journal<space/></arg><arg name="accessdate">27 December 2013</arg><arg name="doi">10.1136/bmj.f5675</arg><arg name="volume">347</arg><arg name="pages">f5675</arg></template></extension></paragraph><heading level='3'>United States</heading><paragraph>In 1988, there was a confirmed death from CJD of a person from<space/><link><target>Manchester, New Hampshire</target></link>.<space/><link><target>Massachusetts General Hospital</target></link><space/>believed the patient acquired the disease from a surgical instrument at a<space/><link><target>podiatrist</target></link>'s office.<template><target>citation needed</target><arg name="date">November 2013</arg></template><space/>In September 2013, another patient in Manchester was posthumously determined to have died of the disease. The patient had undergone brain surgery at<space/><link><target>Catholic Medical Center</target></link><space/>three months before his death, and a surgical probe used in the procedure was subsequently reused in other operations. Public health officials identified thirteen patients at three hospitals who may have been exposed to the disease through the contaminated probe, but said the risk of anyone's contracting CJD is &quot;extremely low.&quot;<extension extension_name='ref'><template><target>cite web</target><arg name="title">Autopsy confirms rare brain disease in NH patient</arg><arg name="url">http://www.myfoxboston.com/story/23489308/2013/09/20/autopsy-confirms-rare-brain-disease-in-nh-patient</arg><arg name="publisher">MyFoxBoston</arg><arg name="accessdate">20 September 2013</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">NH PATIENT LIKELY DIED OF RARE BRAIN DISEASE</arg><arg name="url">http://bigstory.ap.org/article/surgical-gear-quarantined-over-rare-brain-disease</arg><arg name="publisher">AP</arg><arg name="accessdate">5 September 2013</arg></template></extension><extension extension_name='ref' name="globe"><template><target>cite news</target><arg name="last">Kowalczyk<space/></arg><arg name="first">Liz<space/></arg><arg name="title">5 patients at Cape hospital at risk for rare brain disease<space/></arg><arg name="url">http://www.boston.com/news/local/massachusetts/2013/09/05/cape-cod-hospital-patients-possibly-exposed-brain-disease/CwGauqzFxf6Om8agTvUoAJ/story.html<space/></arg><arg name="work">Boston Globe<space/></arg><arg name="accessdate">25 November 2013<space/></arg><arg name="deadurl">yes<space/></arg><arg name="archiveurl">https://web.archive.org/20130909210818/http://www.boston.com:80/news/local/massachusetts/2013/09/05/cape-cod-hospital-patients-possibly-exposed-brain-disease/CwGauqzFxf6Om8agTvUoAJ/story.html<space/></arg><arg name="archivedate">9 September 2013<space/></arg></template></extension><space/>In 2008, a man in Germantown, Wisconsin died of CJD within four months of finding first symptoms. In June 2013, a woman in Prairie Village, KS died. During her brain autopsy, doctors found out that she had CJD. In January 2015, the former speaker of the<space/><link><target>Utah House of Representatives</target></link>,<space/><link><target>Rebecca D. Lockhart</target></link>, died of the disease within a few weeks of diagnosis.<extension extension_name='ref'>http://www.heraldextra.com/news/local/central/provo/officials-lockhart-died-from-creutzfeldt-jakob-disease/article_ab2ba7d7-26b0-5e7a-8347-3142e5ded8cc.html</extension><space/><link><target>John Carroll (journalist)</target><part>John Carroll</part></link>, former editor of<space/><italics><link><target>The Baltimore Sun</target></link></italics><space/>and<space/><italics><link><target>Los Angeles Times</target></link></italics>, died of CJD in Kentucky in June 2015, after having been diagnosed in January.<extension extension_name='ref'><template><target>cite news</target><arg name="url">http://www.washingtonpost.com/national/john-s-carroll-edited-newspapers-in-baltimore-and-los-angeles-dies-at-73/2015/06/14/65bd5c1a-eac7-11e4-9a6a-c1ab95a0600b_story.html</arg><arg name="title">John S. Carroll, acclaimed newspaper editor in Baltimore and L.A., dies at 73</arg><arg name="last">Schudel</arg><arg name="first">Matt</arg><arg name="newspaper">The Washington Post</arg><arg name="date">June 14, 2015</arg></template></extension></paragraph><paragraph>Other fatalities have occurred in<space/><link><target>Minnesota</target></link><space/>and Pennsylvania and have been tracked by the state health department since 1991, averaging 5 deaths per year or 1.3 deaths per million persons.<extension extension_name='ref'>http://www.health.state.mn.us/divs/idepc/diseases/cjd/ CJD trends</extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>CJD (disambiguation)</target></link></listitem><listitem><link><target>Chronic traumatic encephalopathy</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>3</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://memory.ucsf.edu/cjd'>UCSF Memory and Aging Center</link>education website from a CJD patient care and research center<list type='bullet'><listitem><link type='external' href='https://www.youtube.com/ucsfmemoryandaging'>UCSF Memory and Aging Center YouTube channel</link><space/>with films about CJD</listitem></list></listitem><listitem><link type='external' href='http://ind.ucsf.edu/'>Institute for Neurodegenerative Diseases (IND)</link>a basic science research institute working on a cure for CJD</listitem><listitem><template><target>DMOZ</target><arg>Health/Conditions_and_Diseases/Neurological_Disorders/Infections/Creutzfeldt_Jakob_Disease/</arg></template></listitem><listitem><link type='external' href='http://www.youtube.com/watch?v=Xws0_I-xyOI'>CJD animation</link></listitem></list><paragraph><template><target>Prion diseases</target></template><template><target>Mental and behavioural disorders</target><arg name="selected"><space/>neurological</arg></template><template><target>Consumer Food Safety</target></template></paragraph><paragraph><template><target>DEFAULTSORT:Creutzfeldt-Jakob Disease</target></template><link><target>Category:Transmissible spongiform encephalopathies</target></link><link><target>Category:Neurodegenerative disorders</target></link><link><target>Category:Rare infectious diseases</target></link><link><target>Category:Psychiatric diagnosis</target></link></paragraph></article>